Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Epidermal Growth Factor Receptor
74%
Alectinib
71%
Pharmacokinetics
59%
Lung Cancer
57%
Osimertinib
50%
Progression Free Survival
45%
Neoplasm
33%
Protein Tyrosine Kinase Inhibitor
26%
Cohort Study
26%
Circulating Tumor DNA
24%
Esomeprazole
23%
Anaplastic Lymphoma Kinase
23%
Afatinib
23%
Adverse Event
22%
Erlotinib
19%
Epidermal Growth Factor Receptor Kinase Inhibitor
16%
Solid Malignant Neoplasm
15%
Clinical Trial
15%
Overall Survival
15%
Bioavailability
13%
Tolerability
12%
Diseases
12%
Cardiotoxicity
11%
Dairy Cattle
11%
Randomized Controlled Trial
11%
Phase IV
11%
Chemotherapy
11%
Hepatotoxicity
11%
Peritoneal Mesothelioma
11%
Paclitaxel
11%
Trastuzumab Emtansine
11%
Immunotherapy
11%
Bevacizumab
11%
Clinical Feature
11%
Combination Therapy
11%
Therapeutic Drug Monitoring
11%
Cetuximab
11%
Crizotinib
11%
Cabozantinib
11%
Biological Marker
10%
Proton Pump Inhibitor
9%
Carboplatin
6%
RNA-Sequencing
5%
Carcinogenesis
5%
Yogurt
5%
Atezolizumab
5%
Pemetrexed
5%
Medicine and Dentistry
Non Small Cell Lung Cancer
64%
Targeted Therapy
57%
Non-Small Cell Lung Cancer
49%
Neoplasm
42%
Epidermal Growth Factor Receptor
35%
Lung Cancer
29%
Exon
28%
Tyrosine-Kinase Inhibitor
23%
Progression Free Survival
20%
Diseases
20%
Overall Survival
20%
Osimertinib
18%
Next Generation Sequencing
17%
Crizotinib
17%
Oncogene
13%
Clinical Feature
13%
Immunotherapy
13%
Cohort Analysis
13%
Central Nervous System Metastasis
11%
Systematic Review
11%
Lifespan
11%
Peritoneum Mesothelioma
11%
Lorlatinib
11%
Bevacizumab
11%
Paclitaxel
11%
Adverse Event
11%
Solid Malignant Neoplasm
11%
Cabozantinib
11%
Resistance Mutation
11%
Central Nervous System
9%
Carcinogenesis
8%
Epidermal Growth Factor Receptor Kinase Inhibitor
8%
Systemic Therapy
7%
Carboplatin
6%
In Situ Hybridization
6%
Malignant Neoplasm
6%
Biopsy Technique
5%
Pemetrexed
5%
Immunohistochemistry
5%
Atezolizumab
5%
